[May 16, 2013]

Research and Markets: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/k7xc6s/pharmapoint) has announced the addition of the "PharmaPoint: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022" report to their offering.

"PharmaPoint: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022." Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT (News - Alert)). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer's Betaseron/Betaferon (IFNß-1b), Biogen's Avonex (IFNß-1a) and Merck's Rebif (IFNß-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming geerics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

The decline in the market size over the forecast period is mainly attributable to a drop in the younger population, especially those within the 40-49 years age group, who are more likely to be diagnosed with MS in Japan. Other important barriers to market growth include biennial price cuts in pharmaceuticals, which reduce the profitability of branded drugs, and government initiatives to increase generics uptake.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.2 Symptoms

4 Disease Management

4.1 Diagnosis

4.2 Treatment Overview

4.2.1 Management of Acute Relapse

4.2.2 Treatment with Disease-Modifying Therapies

4.2.3 Symptomatic Therapies

4.3 Japan

4.3.1 Diagnosis

4.3.2 Clinical Practice

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitor Assessment

5.3 Product Profiles - Major Brands

6 Opportunity and Unmet Need

6.1 Overview

6.2 Unmet Needs

6.2.1 Currently Available MS Drugs Only Provide Partial Benefits

6.2.2 The High Cost of MS Drugs Could Continue to Price out Patients

6.2.3 Safety and Tolerability of Therapy is Undermined by Side Effects

6.2.4 Effective Treatments for Progressive MS Are Still Elusive

6.2.5 Inconvenient Route of Administration and Frequent Dosing Limits Compliance

6.2.6 The Lack of Predictive Biomarkers Delays MS Diagnosis

6.3 Unmet Needs Gap Analysis

6.4 Opportunities

6.4.1 Treatments for Progressive MS

6.4.2 Targeting Patients with Clinically Isolated Syndrome

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Clinical Development

8 Market Outlook

9 Appendix

For more information visit http://www.researchandmarkets.com/research/k7xc6s/pharmapoint

[ Back To TMCnet.com's Homepage ]